4-[2-(2-phenylmorpholino)propyl]phenoxyacetic acid methyl ester hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 4-[2-(2-phenylmorpholino)propyl]phenoxyacetic acid methyl ester hydrochloride
• 英文别名: methyl 2-[4-[2-(2-phenylmorpholin-4-yl)propyl]phenoxy]acetate;hydrochloride
• 化学式: C₂₂H₂₇NO₄*ClH
• 分子量: 405.922
• InChiKey: BDYKSHPGVNKGNI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.66
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  48
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-[2-(2-phenylmorpholino)propyl]phenoxyacetic acid methyl ester hydrochloride 生成 acetic acid;2-[4-[2-(4-oxido-2-phenylmorpholin-4-ium-4-yl)propyl]phenoxy]acetic acid
  参考文献：
  名称：

  REIFFEN, MANFRED;HURNAUS, RUDOLF;SAUTER, ROBERT;GRELL, WOLFGANG;RUPPRECHT+

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(2-hydroxyethyl)-2-(4-carbomethoxymethoxyphenyl)-1-methyl-ethylamine 生成 4-[2-(2-phenylmorpholino)propyl]phenoxyacetic acid methyl ester hydrochloride
  参考文献：
  名称：

  REIFFEN, MANFRED;HURNAUS, RUDOLF;SAUTER, ROBERT;GRELL, WOLFGANG;RUPPRECHT+

  摘要：

  DOI：

文献信息

• Morpholine derivatives, compositions and medicinal use
  申请人：Beecham Group p.l.c.

  公开号：US04607033A1

  公开（公告）日：1986-08-19

  Compounds of formula (I): ##STR1## or a salt thereof, in which W is phenyl optionally substituted by halogen or trifluoromethyl, or a benzofuran-2-yl group, R.sup.1 is hydrogen or methyl, R.sup.2 is carboxyl or a group O--Z--CO.sub.2 H or an ester or amide thereof; a group O--E--NR.sup.3 R.sup.4 or a group O--E--OR.sup.5, wherein R.sup.3, R.sup.4 and R.sup.5 each represents hydrogen or C.sub.1-6 alkyl, Z is a C.sub.1-6 straight or branched alkylene chain, n is 1 or 2, a is 2 or 3, and E is a C.sub.2-7 straight or branched alkylene chain with at least two carbon atoms separating the two heteroatoms in the group R.sup.2 ; a process for the production of such compounds and their use in treating hyperglycaemia and/or obesity.

  公式（I）的化合物：##STR1##或其盐，其中W是苯基，可以选择性地被卤素或三氟甲基取代，或是苯并呋喃-2-基；R.sup.1是氢或甲基，R.sup.2是羧基，或是O-Z-CO.sub.2 H基团的酯或酰胺；O-E-NR.sup.3R.sup.4基团或O-E-OR.sup.5基团，其中R.sup.3，R.sup.4和R.sup.5分别代表氢或C.sub.1-6烷基，Z是C.sub.1-6直链或支链烷基链，n为1或2，a为2或3，E是C.sub.2-7直链或支链烷基链，其中在R.sup.2基团中两个杂原子之间至少有两个碳原子分隔；制备此类化合物的方法以及它们在治疗高血糖和/或肥胖症方面的用途。
• Morpholine derivatives, compositions and method of use
  申请人：Beecham Group p.l.c.

  公开号：US04665072A1

  公开（公告）日：1987-05-12

  Compounds of formula (I): ##STR1## or a salt thereof, in which W is phenyl optionally substituted by halogen or trifluoromethyl, or a benzofuran-2-yl group, R.sup.1 is hydrogen or methyl, R.sup.2 is carboxyl or a group O--Z--CO.sub.2 H or an ester or amide thereof; a group O--E--NR.sup.3 R.sup.4 or a group O--E--OR.sup.5, wherein R.sup.3, R.sup.4 and R.sup.5 each represents hydrogen or C.sub.1-6 alkyl, Z is a C.sub.1-6 straight or branched alkylene chain, n is 1 or 2, a is 2 or 3, and E is a C.sub.2-7 straight or branched alkylene chain with at least two carbon atoms separating the two heteroatoms in the group R.sup.2 ; a process for the production of such compounds and their use in medicine as anti-hyperglycaemic and/or anti-obesity agents.

  式(I)的化合物：##STR1##或其盐，其中W为苯基，可选用卤素或三氟甲基取代，或苯并呋喃-2-基团；R.sup.1为氢或甲基，R.sup.2为羧基或O-Z-CO.sub.2 H基团或其酯或酰胺；O-E-NR.sup.3R.sup.4基团或O-E-OR.sup.5基团，其中R.sup.3，R.sup.4和R.sup.5分别表示氢或C.sub.1-6烷基，Z为C.sub.1-6直链或支链烷基链，n为1或2，a为2或3，E为C.sub.2-7直链或支链烷基链，其中在基团R.sup.2中两个杂原子之间至少有两个碳原子分隔；制备这种化合物的方法以及它们作为抗高血糖和/或抗肥胖剂在医药上的用途。
• Morpholine derivatives, compositions and medicinal uses
  申请人：Beecham Group p.l.c.

  公开号：US04783460A1

  公开（公告）日：1988-11-08

  Compounds of formula (I): ##STR1## or a salt thereof, in which W is phenyl optionally substituted by halogen or trifluoromethyl, or a benzofuran-2-yl group, R.sup.1 is hydrogen or methyl, R.sup.2 is carboxyl or a group O--Z--CO.sub.2 H or an ester or amide thereof; a group O--E--NR.sup.3 R.sup.4 or a group O--E--OR.sup.5, wherein R.sup.3, R.sup.4 and R.sup.5 each represents hydrogen or C.sub.1-6 alkyl, Z is a C.sub.1-6 straight or branched alkylene chain, n is 1 or 2, a is 2 or 3, and E is a C.sub.2-7 straight or branched alkylene chain with at least two carbon atoms separating the two heteroatoms in the group R.sup.2 ; a process for the production of such compounds and their use in treating hyperglycaemia and/or obesity.

  化合物的公式(I)：##STR1## 或其盐，其中W是苯基，可选地被卤素或三氟甲基取代，或苯并呋喃-2-基团，R1是氢或甲基，R2是羧基或O-Z-CO2H基团或其酯或酰胺；O-E-NR3R4基团或O-E-OR5基团，其中R3，R4和R5分别表示氢或C1-6烷基，Z是C1-6直链或支链烷基链，n为1或2，a为2或3，E是C2-7直链或支链烷基链，其中在基团R2中两个杂原子之间至少有两个碳原子分隔；一种制备这种化合物的方法以及它们在治疗高血糖和/或肥胖症中的用途。
• REIFFEN, MANFRED;HURNAUS, RUDOLF;SAUTER, ROBERT;GRELL, WOLFGANG;RUPPRECHT+
  作者：REIFFEN, MANFRED、HURNAUS, RUDOLF、SAUTER, ROBERT、GRELL, WOLFGANG、RUPPRECHT+

  DOI：——

  日期：——
• Morpholine derivatives
  申请人：BEECHAM GROUP PLC

  公开号：EP0140359B1

  公开（公告）日：1989-01-25